scholarly journals Paciente con regurgitación: cómo estudiarla y cuáles son sus principales diagnósticos diferenciales

2021 ◽  
Vol 51 (1) ◽  
Author(s):  
Mariela Dulbecco ◽  
Yolanda Vargas Rodríguez ◽  
Mauricio Guzmán

In gastroenterological practice, gastroesophageal reflux disease is one of the most frequent diagnoses. In this article the potential confounding of gastroesophageal reflux will be raised. According to the Montreal definition, “is a condition that develops when the reflux of stomach contents into the esophagus causes troublesome symptoms and/or complications.” However, it is becoming increasingly clear that sometimes symptoms suspected to be caused by gastroesophageal reflux disease are the expression of other functional and behavioral disorders or even structural lesions. From this complexity arise reflux confounding, where rumination and supragastric belching may present symptoms similar to gastroesophageal reflux disease, be initially treated with the proton pump inhibitor-based guidelines, and thus be mistakenly targeted. Likewise, regurgitation may be the symptomatic expression of different functional disorders and not exclusively a “typical” symptom of gastroesophageal reflux disease. Hence the need and the challenge for the treating physician to correctly identify the pathophysiological mechanisms responsible for the patient’s symptoms for a correct therapeutic approach.

2008 ◽  
Vol 149 (40) ◽  
pp. 1881-1888 ◽  
Author(s):  
Márk Juhász ◽  
Zsolt Tulassay

A protonpumpagátlók (protonpumpa-inhibitorok, PPI) bevezetése új fejezetet nyitott a gastrooesophagealis refluxbetegség (gastroesophageal reflux disease, GERD) kezelésében. A betegek kisebb, de nem jelentéktelen hányadában azonban a PPI sem hatékony. Ilyen esetekben az első kérdés mindig az, hogy a tünetek valóban GERD-nek tulajdoníthatók-e, vagy egyéb betegség után kell kutatnunk. Ha a GERD a legvalószínűbb lehetőség, akkor a további vizsgálatok és a több támadáspontú kezelés előtt fel kell térképeznünk a beteg együttműködését (compliance). Ha az eredménytelen PPI-kezelés hátterében nem helytelenül kezelt GERD áll, akkor számos egyéb kórkép lehetőségét is fel kell vetnünk. Összefoglaló közleményünkben az elkülönítő diagnosztikai kérdésekről adunk áttekintést.


2020 ◽  
Vol 9 (9) ◽  
pp. 2705
Author(s):  
Toshihiro Nishizawa ◽  
Kiyoto Mori ◽  
Shuntaro Yoshida ◽  
Hirotoshi Ebinuma ◽  
Osamu Toyoshima ◽  
...  

Background and Aim: In gastroesophageal reflux disease (GERD), the additive effect of mosapride to a proton pump inhibitor (PPI) is still controversial. This meta-analysis integrated randomized controlled trials (RCTs) in which mosapride combined with a PPI was compared with a PPI alone in GERD treatment. Methods: RCTs were systematically searched with the PubMed, Cochrane library, Web of Science, and the Igaku-Chuo-Zasshi database. We combined the data from the RCTs with a random effects model, calculated the standardized mean difference (SMD) and pooled the risk difference (RD) with 95% confidence intervals (CIs). Results: We included nine RCTs in the present meta-analysis. In the mosapride combined with PPI group, the improvement of the symptom score was significantly greater than that in the PPI alone group without significant heterogeneity (SMD: −0.28, 95% CI: −0.45 to −0.12, p = 0.0007). In the mosapride combined with PPI group, the symptom score after treatment was significantly lower than that in the PPI alone group (SMD: −0.24, 95% CI: −0.42 to −0.06, p = 0.007). Conclusions: Mosapride combined with a PPI significantly improved the reflux symptom score compared with that of PPI alone.


Sign in / Sign up

Export Citation Format

Share Document